The therapeutic response obtained in some patients is quite promising and deserves additional development of this compound under a Phase II clinical trial. The recommended dose for Phase II studies is 0.18 mg/m2.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.